Despite being recognized since the first descriptions of the syndrome, negative symptom definition, assessment and treatment are still far from satisfactory. 2, 6, 9 In the past decade, a large consensus has been reached on definition of the negative symptoms, 6 ,9 a better assessment has been advocated, and new assessment instruments have been developed. 10, 11 A better assessment is aimed to reduce significant overlaps with cognitive dysfunctions, disorganization and functional measures, as well as to reduce heterogeneity of negative symptoms and foster improved pathophysiological hypotheses. 12 As illustrated below, there are, however, several challenges to overcome before these needs can be met.
For the purpose of reducing heterogeneity, it has generally been recognized that negative symptoms cluster in 2 separate domains 6, 9, 12 : avoliton/apathy (including the experiential negative symptoms-anhedonia, avolition, and asociality) and expressive deficit (including alogia and blunted affect). It was initially thought that the use of the domain scores instead of a total negative symptom score would significantly advance research on pathophysiological mechanisms. However, the 2 domains were derived by factor analytic studies using different first-and second-generation scales, which included completely different items, some of which did not belong to the negative symptom construct. This can be illustrated by the confirmatory factor analysis by Liemburg et al, 13 who analyzed Positive and Negative Syndrome Scale (PANSS) items reported by literature as clustering in the 2 domains "Core negative symptoms" and "Social emotive withdrawal." The "Core negative symptoms" factor included N1 "Flat affect," N3 "Poor rapport," N6 "Lack of spontaneity and flow of conversation," G5 "Mannerisms and posturing," G7 "Motor retardation," and G13 "Avolition," whereas the "Social emotive withdrawal" factor, included N2 "Emotional withdrawal," N4 "Apathetic social withdrawal," and G16 "Active social avoidance." It is apparent that these factors include items related to the disorganization dimension (G5 and G13), depression (G7) and positive symptoms (G16), which rate secondary negative symptoms due to anxiety, depression, or psychosis. Furthermore, the domains do not correspond to those obtained with other old scales [14] [15] [16] or new instruments.
11,17,18
Another major problem has been the assessment of the experiential symptoms by the old instruments. As a matter of fact, avoliton, asociality, and anhedonia were all covered by the Scale for the Assessment of Negative Symptoms (SANS) but were assessed considering only the behavioral level and not the subjective interest or motivation. Thus, their severity, rated using the SANS, indicated reduction or lack of goal-directed activity, social relationships, and involvement in pleasurable activities, which might reflect other problems more than the presence of negative symptoms. For instance, a subject with moderate-severe delusion of reference might not get involved in any social activity to limit the distress caused by the delusion. Among the old instruments only the Schedule for the Deficit Syndrome adequately assessed the experiential domain considering the internal experience of motivation and interest; however, this scale did not assess anhedonia.
A further source of heterogeneity is represented by the secondary negative symptoms, that is, those symptoms due to factors such as moderate or severe positive symptoms, interfering with functioning (as exemplified above), clinically significant levels of depression, or parkinsonism caused by antipsychotic drugs. These symptoms might be more represented in certain phases of the disorder (eg, during the acute phase, or early in the disease course) or for certain classes of antipsychotic drugs (eg, first-generation antipsychotics might induce more extrapyramidal side effects or depression than second-generation ones). Furthermore, they are less enduring than the primary negative symptoms 7 and might be heterogeneous as to their pathophysiological mechanisms. 7, 12 Unlike primary negative symptoms, some of the secondary ones are amenable to treatment. 19 For this reason, more homogeneous subject groups with the characterization of persistent negative symptoms (which requires to control for main sources of secondary negative symptoms) is today required in investigations on possible innovative treatments for negative symptoms.
The challenges listed above clearly illustrate that the field has an urgent need to overcome previous limitations, and the identification of biomarkers and pathophysiological mechanisms of negative symptoms is still an important task of brain imaging and electrophysiological research.
This special issue of Clinical EEG and Neuroscience is dedicated to several hot topics concerning negative symptom research.
The viewpoint by Judith Ford underscores the intriguing scarcity of electrophysiological findings concerning symptoms, and particularly negative symptoms, with regard to the bulk of evidence concerning the diagnosis of schizophrenia. The reviews, authored by Kazuki Sueyoshi et al and Lynn Mørch-Johnsen et al, respectively, summarize electrophysiological and brain imaging studies on negative symptoms. They illustrate the evolution of paradigms and main results of these studies.
Ezgi Ince and Alp Üçok reviewed neurocognitive and brain imaging findings concerning persistent negative symptoms.
Maria Pontillo et al provide a systematic review on transcranial direct current stimulation (tDCS) in the treatment of negative symptoms, highlighting heterogeneity of methodology as a main issue.
Three original research reports are also included. Mette Nielsen et al investigated, in first-episode patients, antipsychotic-related functional magnetic resonance imaging (fMRI) changes in the brain reward system, considered one of the main substrate of the motivation deficits of patients with schizophrenia. Vignapiano et al illustrate the contribution provided by electrophysiological investigations in the separation of cognitive and motivational deficits in treated, clinically stable subjects with schizophrenia. Amodio et al present brain imaging findings that highlight the heterogeneity of the 2 domains of negative symptoms, and indicate that avolition/apathy is subtended by different alterations in brain connectivity with regard to cognitive deficits.
We hope this special issue will stimulate future electrophysiological and imaging investigations to use more appropriate methods of negative symptom assessment, to control for main sources of secondary negative symptoms, and to focus on the separate experiential and expressive domains.
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